Sipatrigine

Drug Profile

Sipatrigine

Alternative Names: 619C89; B 619C; BW 619C89

Latest Information Update: 24 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-ischaemics
  • Mechanism of Action Calcium channel antagonists; Glutamate-antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cerebral ischaemia; Stroke

Most Recent Events

  • 30 Oct 2001 Suspended - Phase-II for Cerebral ischaemia in United Kingdom (unspecified route)
  • 30 Oct 2001 Suspended - Phase-II for Stroke in France (unspecified route)
  • 30 Oct 2001 Suspended - Phase-II for Stroke in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top